Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Publisher Correction: Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer.

Chen J, Guccini I, Di Mitri D, Brina D, Revandkar A, Sarti M, Pasquini E, Alajati A, Pinton S, Losa M, Civenni G, Catapano CV, Sgrignani J, Cavalli A, D'Antuono R, Asara JM, Morandi A, Chiarugi P, Crotti S, Agostini M, Montopoli M, Masgras I, Rasola A, Garcia-Escudero R, Delaleu N, Rinaldi A, Bertoni F, de Bono J, Carracedo A, Alimonti A.

Nat Genet. 2018 Aug 8. doi: 10.1038/s41588-018-0181-1. [Epub ahead of print]

PMID:
30089860
2.

Overview of Genetically Engineered Mouse Models of Prostate Cancer and Their Applications in Drug Discovery.

Civenni G, Carbone GM, Catapano CV.

Curr Protoc Pharmacol. 2018 Jun;81(1):e39. doi: 10.1002/cpph.39. Epub 2018 Jun 7.

PMID:
29927081
3.

Structural Biology of STAT3 and Its Implications for Anticancer Therapies Development.

Sgrignani J, Garofalo M, Matkovic M, Merulla J, Catapano CV, Cavalli A.

Int J Mol Sci. 2018 May 28;19(6). pii: E1591. doi: 10.3390/ijms19061591. Review.

4.

Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer.

Chen J, Guccini I, Di Mitri D, Brina D, Revandkar A, Sarti M, Pasquini E, Alajati A, Pinton S, Losa M, Civenni G, Catapano CV, Sgrignani J, Cavalli A, D'Antuono R, Asara JM, Morandi A, Chiarugi P, Crotti S, Agostini M, Montopoli M, Masgras I, Rasola A, Garcia-Escudero R, Delaleu N, Rinaldi A, Bertoni F, Bono J, Carracedo A, Alimonti A.

Nat Genet. 2018 Feb;50(2):219-228. doi: 10.1038/s41588-017-0026-3. Epub 2018 Jan 15. Erratum in: Nat Genet. 2018 Aug 8;:.

5.

Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.

Janouskova H, El Tekle G, Bellini E, Udeshi ND, Rinaldi A, Ulbricht A, Bernasocchi T, Civenni G, Losa M, Svinkina T, Bielski CM, Kryukov GV, Cascione L, Napoli S, Enchev RI, Mutch DG, Carney ME, Berchuck A, Winterhoff BJN, Broaddus RR, Schraml P, Moch H, Bertoni F, Catapano CV, Peter M, Carr SA, Garraway LA, Wild PJ, Theurillat JP.

Nat Med. 2017 Sep;23(9):1046-1054. doi: 10.1038/nm.4372. Epub 2017 Aug 14.

6.

Natural antisense transcripts drive a regulatory cascade controlling c-MYC transcription.

Napoli S, Piccinelli V, Mapelli SN, Pisignano G, Catapano CV.

RNA Biol. 2017 Dec 2;14(12):1742-1755. doi: 10.1080/15476286.2017.1356564. Epub 2017 Oct 11.

7.

Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells.

Genini D, Brambilla L, Laurini E, Merulla J, Civenni G, Pandit S, D'Antuono R, Perez L, Levy DE, Pricl S, Carbone GM, Catapano CV.

Proc Natl Acad Sci U S A. 2017 Jun 20;114(25):E4924-E4933. doi: 10.1073/pnas.1615730114. Epub 2017 Jun 5.

8.

A promoter-proximal transcript targeted by genetic polymorphism controls E-cadherin silencing in human cancers.

Pisignano G, Napoli S, Magistri M, Mapelli SN, Pastori C, Di Marco S, Civenni G, Albino D, Enriquez C, Allegrini S, Mitra A, D'Ambrosio G, Mello-Grand M, Chiorino G, Garcia-Escudero R, Varani G, Carbone GM, Catapano CV.

Nat Commun. 2017 May 30;8:15622. doi: 10.1038/ncomms15622.

9.

Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors.

Stathis A, Hess D, von Moos R, Homicsko K, Griguolo G, Joerger M, Mark M, Ackermann CJ, Allegrini S, Catapano CV, Xyrafas A, Enoiu M, Berardi S, Gargiulo P, Sessa C; Swiss Group for Clinical Cancer Research (SAKK).

Invest New Drugs. 2017 Dec;35(6):766-772. doi: 10.1007/s10637-017-0454-z. Epub 2017 Mar 20.

PMID:
28317088
10.

MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression.

Dallavalle C, Albino D, Civenni G, Merulla J, Ostano P, Mello-Grand M, Rossi S, Losa M, D'Ambrosio G, Sessa F, Thalmann GN, Garcia-Escudero R, Zitella A, Chiorino G, Catapano CV, Carbone GM.

J Clin Invest. 2016 Dec 1;126(12):4585-4602. doi: 10.1172/JCI86505. Epub 2016 Nov 7.

11.

Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells.

Rabi T, Catapano CV.

Tumour Biol. 2016 Sep;37(9):12455-12464. Epub 2016 Jun 22.

PMID:
27333990
12.

A Small-Molecule Inhibitor of Lin28.

Roos M, Pradère U, Ngondo RP, Behera A, Allegrini S, Civenni G, Zagalak JA, Marchand JR, Menzi M, Towbin H, Scheuermann J, Neri D, Caflisch A, Catapano CV, Ciaudo C, Hall J.

ACS Chem Biol. 2016 Oct 21;11(10):2773-2781. Epub 2016 Aug 22.

PMID:
27548809
13.

The ETS factor ESE3/EHF represses IL-6 preventing STAT3 activation and expansion of the prostate cancer stem-like compartment.

Albino D, Civenni G, Rossi S, Mitra A, Catapano CV, Carbone GM.

Oncotarget. 2016 Nov 22;7(47):76756-76768. doi: 10.18632/oncotarget.12525.

14.

Activation of the Lin28/let-7 Axis by Loss of ESE3/EHF Promotes a Tumorigenic and Stem-like Phenotype in Prostate Cancer.

Albino D, Civenni G, Dallavalle C, Roos M, Jahns H, Curti L, Rossi S, Pinton S, D'Ambrosio G, Sessa F, Hall J, Catapano CV, Carbone GM.

Cancer Res. 2016 Jun 15;76(12):3629-43. doi: 10.1158/0008-5472.CAN-15-2665. Epub 2016 May 2.

15.

EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB.

Civenni G, Longoni N, Costales P, Dallavalle C, García Inclán C, Albino D, Nuñez LE, Morís F, Carbone GM, Catapano CV.

Mol Cancer Ther. 2016 May;15(5):806-18. doi: 10.1158/1535-7163.MCT-15-0791. Epub 2016 Jan 29.

16.

Molecular Determinants for Unphosphorylated STAT3 Dimerization Determined by Integrative Modeling.

Sgrignani J, Olsson S, Ekonomiuk D, Genini D, Krause R, Catapano CV, Cavalli A.

Biochemistry. 2015 Sep 8;54(35):5489-501. doi: 10.1021/bi501529x. Epub 2015 Aug 25.

PMID:
26283080
17.

A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours.

Kalathur M, Toso A, Chen J, Revandkar A, Danzer-Baltzer C, Guccini I, Alajati A, Sarti M, Pinton S, Brambilla L, Di Mitri D, Carbone G, Garcia-Escudero R, Padova A, Magnoni L, Tarditi A, Maccari L, Malusa F, Kalathur RK, A Pinna L, Cozza G, Ruzzene M, Delaleu N, Catapano CV, Frew IJ, Alimonti A.

Nat Commun. 2015 Jun 18;6:7227. doi: 10.1038/ncomms8227.

PMID:
26085373
18.

Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3).

Brambilla L, Genini D, Laurini E, Merulla J, Perez L, Fermeglia M, Carbone GM, Pricl S, Catapano CV.

Mol Oncol. 2015 Jun;9(6):1194-206. doi: 10.1016/j.molonc.2015.02.012. Epub 2015 Mar 5.

19.

Short loop-targeting oligoribonucleotides antagonize Lin28 and enable pre-let-7 processing and suppression of cell growth in let-7-deficient cancer cells.

Roos M, Rebhan MA, Lucic M, Pavlicek D, Pradere U, Towbin H, Civenni G, Catapano CV, Hall J.

Nucleic Acids Res. 2015 Jan;43(2):e9. doi: 10.1093/nar/gku1090. Epub 2014 Nov 6.

20.

Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity.

Toso A, Revandkar A, Di Mitri D, Guccini I, Proietti M, Sarti M, Pinton S, Zhang J, Kalathur M, Civenni G, Jarrossay D, Montani E, Marini C, Garcia-Escudero R, Scanziani E, Grassi F, Pandolfi PP, Catapano CV, Alimonti A.

Cell Rep. 2014 Oct 9;9(1):75-89. doi: 10.1016/j.celrep.2014.08.044. Epub 2014 Sep 25.

21.

RNAi-mediated silencing of Myc transcription inhibits stem-like cell maintenance and tumorigenicity in prostate cancer.

Civenni G, Malek A, Albino D, Garcia-Escudero R, Napoli S, Di Marco S, Pinton S, Sarti M, Carbone GM, Catapano CV.

Cancer Res. 2013 Nov 15;73(22):6816-27. doi: 10.1158/0008-5472.CAN-13-0615. Epub 2013 Sep 24.

22.

Structurally flexible triethanolamine-core poly(amidoamine) dendrimers as effective nanovectors to deliver RNAi-based therapeutics.

Liu X, Liu C, Catapano CV, Peng L, Zhou J, Rocchi P.

Biotechnol Adv. 2014 Jul-Aug;32(4):844-52. doi: 10.1016/j.biotechadv.2013.08.001. Epub 2013 Aug 9. Review.

PMID:
23938269
23.

Differential expression of testin and survivin in breast cancer subtypes.

Sarti M, Pinton S, Limoni C, Carbone GM, Pagani O, Cavalli F, Catapano CV.

Oncol Rep. 2013 Aug;30(2):824-32. doi: 10.3892/or.2013.2502. Epub 2013 May 28.

PMID:
23715752
24.

ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-κB and drives prostate cancer progression.

Longoni N, Sarti M, Albino D, Civenni G, Malek A, Ortelli E, Pinton S, Mello-Grand M, Ostano P, D'Ambrosio G, Sessa F, Garcia-Escudero R, Thalmann GN, Chiorino G, Catapano CV, Carbone GM.

Cancer Res. 2013 Jul 15;73(14):4533-47. doi: 10.1158/0008-5472.CAN-12-4537. Epub 2013 May 16.

25.

Selection of optimal combinations of target genes for therapeutic multi-gene silencing based on miRNA co-regulation.

Malek A, Gyorffy B, Catapano CV, Schäfer R.

Cancer Gene Ther. 2013 May;20(5):326-9. doi: 10.1038/cgt.2013.20. Epub 2013 Apr 26.

PMID:
23618947
26.

Transcriptional and Non-Transcriptional Functions of PPARβ/δ in Non-Small Cell Lung Cancer.

Genini D, Garcia-Escudero R, Carbone GM, Catapano CV.

PLoS One. 2012;7(9):e46009. doi: 10.1371/journal.pone.0046009. Epub 2012 Sep 25.

27.

Aberrant expression of the neuronal-specific protein DCDC2 promotes malignant phenotypes and is associated with prostate cancer progression.

Longoni N, Kunderfranco P, Pellini S, Albino D, Mello-Grand M, Pinton S, D'Ambrosio G, Sarti M, Sessa F, Chiorino G, Catapano CV, Carbone GM.

Oncogene. 2013 May 2;32(18):2315-24, 2324.e1-4. doi: 10.1038/onc.2012.245. Epub 2012 Jun 25.

PMID:
22733135
28.

An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.

Parma G, Mancari R, Del Conte G, Scambia G, Gadducci A, Hess D, Katsaros D, Sessa C, Rinaldi A, Bertoni F, Vitali A, Catapano CV, Marsoni S, van de Velde H, Colombo N.

Int J Gynecol Cancer. 2012 Jun;22(5):792-800. doi: 10.1097/IGC.0b013e318251051a.

PMID:
22635029
29.

Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer.

Malek A, Núñez LE, Magistri M, Brambilla L, Jovic S, Carbone GM, Morís F, Catapano CV.

PLoS One. 2012;7(4):e35130. doi: 10.1371/journal.pone.0035130. Epub 2012 Apr 19.

30.

ESE3/EHF controls epithelial cell differentiation and its loss leads to prostate tumors with mesenchymal and stem-like features.

Albino D, Longoni N, Curti L, Mello-Grand M, Pinton S, Civenni G, Thalmann G, D'Ambrosio G, Sarti M, Sessa F, Chiorino G, Catapano CV, Carbone GM.

Cancer Res. 2012 Jun 1;72(11):2889-900. doi: 10.1158/0008-5472.CAN-12-0212. Epub 2012 Apr 13.

31.

The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression.

Babbio F, Pistore C, Curti L, Castiglioni I, Kunderfranco P, Brino L, Oudet P, Seiler R, Thalman GN, Roggero E, Sarti M, Pinton S, Mello-Grand M, Chiorino G, Catapano CV, Carbone GM, Bonapace IM.

Oncogene. 2012 Nov 15;31(46):4878-87. doi: 10.1038/onc.2011.641. Epub 2012 Feb 13.

PMID:
22330138
32.

Active-targeted nanotherapy strategies for prostate cancer.

Katsogiannou M, Peng L, Catapano CV, Rocchi P.

Curr Cancer Drug Targets. 2011 Oct;11(8):954-65. Review.

PMID:
21861840
33.

Small RNA-directed transcriptional control: new insights into mechanisms and therapeutic applications.

Pastori C, Magistri M, Napoli S, Carbone GM, Catapano CV.

Cell Cycle. 2010 Jun 15;9(12):2353-62. Epub 2010 Jun 15. Review.

PMID:
20519954
34.

PAMAM dendrimers for siRNA delivery: computational and experimental insights.

Pavan GM, Posocco P, Tagliabue A, Maly M, Malek A, Danani A, Ragg E, Catapano CV, Pricl S.

Chemistry. 2010 Jul 12;16(26):7781-95. doi: 10.1002/chem.200903258.

PMID:
20496352
35.

ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer.

Kunderfranco P, Mello-Grand M, Cangemi R, Pellini S, Mensah A, Albertini V, Malek A, Chiorino G, Catapano CV, Carbone GM.

PLoS One. 2010 May 10;5(5):e10547. doi: 10.1371/journal.pone.0010547.

36.

Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts.

Previdi S, Malek A, Albertini V, Riva C, Capella C, Broggini M, Carbone GM, Rohr J, Catapano CV.

Gynecol Oncol. 2010 Aug 1;118(2):182-8. doi: 10.1016/j.ygyno.2010.03.020. Epub 2010 May 8.

37.

A sensitive polymerase chain reaction-based method for detection and quantification of metastasis in human xenograft mouse models.

Malek A, Catapano CV, Czubayko F, Aigner A.

Clin Exp Metastasis. 2010 Apr;27(4):261-71. doi: 10.1007/s10585-010-9324-1. Epub 2010 Apr 4.

PMID:
20364399
38.

Impact of genomic methylation on radiation sensitivity of colorectal carcinoma.

Hofstetter B, Niemierko A, Forrer C, Benhattar J, Albertini V, Pruschy M, Bosman FT, Catapano CV, Ciernik IF.

Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1512-9. doi: 10.1016/j.ijrobp.2009.10.037.

PMID:
20338477
39.

Mechanisms of triplex DNA-mediated inhibition of transcription initiation in cells.

Jain A, Magistri M, Napoli S, Carbone GM, Catapano CV.

Biochimie. 2010 Mar;92(3):317-20. doi: 10.1016/j.biochi.2009.12.012. Epub 2010 Jan 1.

PMID:
20045441
40.

Promoter-specific transcriptional interference and c-myc gene silencing by siRNAs in human cells.

Napoli S, Pastori C, Magistri M, Carbone GM, Catapano CV.

EMBO J. 2009 Jun 17;28(12):1708-19. doi: 10.1038/emboj.2009.139. Epub 2009 May 21.

41.

Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours.

Cresta S, Sessa C, Catapano CV, Gallerani E, Passalacqua D, Rinaldi A, Bertoni F, Viganò L, Maur M, Capri G, Maccioni E, Tosi D, Gianni L.

Eur J Cancer. 2008 Sep;44(13):1829-34. doi: 10.1016/j.ejca.2008.05.022. Epub 2008 Jul 17.

PMID:
18640031
42.
43.

Daunomycin-TFO Conjugates for Downregulation of Gene Expression.

Capobianco ML, Catapano CV.

Top Curr Chem. 2008;283:45-71. doi: 10.1007/128_2007_2.

PMID:
23605628
44.

Reduced expression and tumor suppressor function of the ETS transcription factor ESE-3 in prostate cancer.

Cangemi R, Mensah A, Albertini V, Jain A, Mello-Grand M, Chiorino G, Catapano CV, Carbone GM.

Oncogene. 2008 May 1;27(20):2877-85. Epub 2007 Nov 26.

PMID:
18037958
45.

Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma.

Rinaldi A, Poretti G, Kwee I, Zucca E, Catapano CV, Tibiletti MG, Bertoni F.

Leuk Lymphoma. 2007 Feb;48(2):410-2. No abstract available.

PMID:
17325905
46.

Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas.

Lacrima K, Rinaldi A, Vignati S, Martin V, Tibiletti MG, Gaidano G, Catapano CV, Bertoni F.

Leuk Lymphoma. 2007 Jan;48(1):158-67.

PMID:
17325859
47.
48.

Control of peroxisome proliferator-activated receptor fate by the ubiquitinproteasome system.

Genini D, Catapano CV.

J Recept Signal Transduct Res. 2006;26(5-6):679-92. Review.

PMID:
17118805
49.

Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells.

Vignati S, Albertini V, Rinaldi A, Kwee I, Riva C, Oldrini R, Capella C, Bertoni F, Carbone GM, Catapano CV.

Neoplasia. 2006 Oct;8(10):851-61.

50.

Synthesis and anticancer activity of cyclopalladated complexes containing 4-hydroxy-acridine.

Pucci D, Albertini V, Bloise R, Bellusci A, Cataldi A, Catapano CV, Ghedini M, Crispini A.

J Inorg Biochem. 2006 Sep;100(9):1575-8. Epub 2006 May 5.

PMID:
16828871

Supplemental Content

Loading ...
Support Center